Tracer library / [18F]AlF-LNC1007

[18F]AlF-LNC1007

Also written as [F-18]AlF-LNC1007
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
Reported once
Syntheses indexed
0
Renal cell carcinoma

What it is

Compound class
FAPI-RGD heterodimer (dual FAP/integrin αvβ3-targeting peptide conjugate)
Target / mechanism
Dual-targeting of fibroblast activation protein (FAP) and integrin αvβ3 PMID 40365277
Clinical application
PET/CT imaging of renal cell carcinoma PMID 40365277
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG/[18F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma.
    2025 · Theranostics · Clinical study

Need this precursor?We can point you to suppliers for [18F]AlF-LNC1007, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40365277. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40365277: 'FAPI-RGD precursor (LNC1007)'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: F-18 is a positron emitter used only for PET imaging. Linked articles: PMID 40365277.
Ask a question